The FDA has deemed cross linking safe for the treatment of keratoconus eye disease, largely due to the efforts of the Massachusetts based Avedro company.
Until now, because this treatment has only been done in FDA studies or off label in the U.S., it had been expensive and the protocols were often restrictive, so many doctors were hesitant to prescribe it for their patients. FDA approval will allow many more patients to seek treatment for their bulging corneas, and in many it may be curative.
Oops! An active online subscription is required to access this content.
Please login below or Subscribe today!